EBBINGHAUS: Evolocumab does not affect cognitive outcomes

18:44 EDT 18 Mar 2017 | Healio

WASHINGTON — The addition of evolocumab to statin therapy did not result in memory loss or other cognitive issues, according to results of the EBBINGHAUS study.The investigators of FOURIER, which compared evolocumab (Repatha, Amgen) vs. placebo for clinical outcomes in patients with atherosclerotic CVD and elevated LDL on background statin therapy, undertook a cognitive substudy because small studies and case series had raised concerns that statins negatively impact cognitive outcomes, later disproven by larger studies, Robert P. Giugliano, MD, SM, cardiovascular medicine specialist at Brigham and Women’s Hospital and a senior investigator at the Thrombolysis in Myocardial Infarction Study Group, said during a presentation at the American College of Cardiology Scientific Session.

Original Article: EBBINGHAUS: Evolocumab does not affect cognitive outcomes


More From BioPortfolio on "EBBINGHAUS: Evolocumab does not affect cognitive outcomes"

Quick Search

Relevant Topics

Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...